WO2001027282A8 - Plant virus particles with exogenous internal eitopes - Google Patents

Plant virus particles with exogenous internal eitopes

Info

Publication number
WO2001027282A8
WO2001027282A8 PCT/US2000/028430 US0028430W WO0127282A8 WO 2001027282 A8 WO2001027282 A8 WO 2001027282A8 US 0028430 W US0028430 W US 0028430W WO 0127282 A8 WO0127282 A8 WO 0127282A8
Authority
WO
WIPO (PCT)
Prior art keywords
expression
eitopes
viruses
virus particles
plant virus
Prior art date
Application number
PCT/US2000/028430
Other languages
French (fr)
Other versions
WO2001027282A1 (en
Inventor
Koen Hellendoorn
Tim Jones
Original Assignee
Dow Chemical Co
Koen Hellendoorn
Tim Jones
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dow Chemical Co, Koen Hellendoorn, Tim Jones filed Critical Dow Chemical Co
Priority to AU10852/01A priority Critical patent/AU785020B2/en
Priority to US10/110,511 priority patent/US7135282B1/en
Priority to BR0014861-0A priority patent/BR0014861A/en
Priority to CA002387626A priority patent/CA2387626A1/en
Priority to JP2001530485A priority patent/JP2003534771A/en
Priority to MXPA02003789A priority patent/MXPA02003789A/en
Priority to IL14907700A priority patent/IL149077A0/en
Priority to EP00972153A priority patent/EP1235910A1/en
Priority to HR20000702A priority patent/HRP20000702A2/en
Publication of WO2001027282A1 publication Critical patent/WO2001027282A1/en
Publication of WO2001027282A8 publication Critical patent/WO2001027282A8/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8201—Methods for introducing genetic material into plant cells, e.g. DNA, RNA, stable or transient incorporation, tissue culture methods adapted for transformation
    • C12N15/8202—Methods for introducing genetic material into plant cells, e.g. DNA, RNA, stable or transient incorporation, tissue culture methods adapted for transformation by biological means, e.g. cell mediated or natural vector
    • C12N15/8203—Virus mediated transformation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
    • C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
    • C12N15/8257—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18711—Rubulavirus, e.g. mumps virus, parainfluenza 2,4
    • C12N2760/18722—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20111—Lyssavirus, e.g. rabies virus
    • C12N2760/20122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

The present invention relates to the expression of peptides on viral particles, and more particularly to the expression of peptides on the interior of the viral capsid. Methods are described for modifying viruses so that exogenous epitopes are expressed on the interior of the viral capsid. Viruses that can be modified include (+) stranded RNA viruses, especially plant (+) stranded RNA viruses such as the cowpea mosaic virus. Internal expression is especially useful for the expression of hydrophobic epitopes. The modified viral particles also find use as vaccines and as such are capable of eliciting an immune response.
PCT/US2000/028430 1999-10-14 2000-10-13 Plant virus particles with exogenous internal eitopes WO2001027282A1 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
AU10852/01A AU785020B2 (en) 1999-10-14 2000-10-13 Plant Virus particles with exogenous internal eitopes
US10/110,511 US7135282B1 (en) 1999-10-14 2000-10-13 Viral particles with exogenous internal epitopes
BR0014861-0A BR0014861A (en) 1999-10-14 2000-10-13 Viral particles with exogenous internal epitopes
CA002387626A CA2387626A1 (en) 1999-10-14 2000-10-13 Viral particles with exogenous internal epitopes
JP2001530485A JP2003534771A (en) 1999-10-14 2000-10-13 Virus particles with foreign internal epitopes
MXPA02003789A MXPA02003789A (en) 1999-10-14 2000-10-13 Plant virus particles with exogenous internal eitopes.
IL14907700A IL149077A0 (en) 1999-10-14 2000-10-13 Viral particles with exogenous internal epitopes
EP00972153A EP1235910A1 (en) 1999-10-14 2000-10-13 Plant virus particles with exogenous internal eitopes
HR20000702A HRP20000702A2 (en) 2000-10-13 2000-10-19 Viral particles with exogenous internal epitopes

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9924352.9 1999-10-14
GBGB9924352.9A GB9924352D0 (en) 1999-10-14 1999-10-14 Methods,compositions and applications relating to the generation of novel plant viral particles

Publications (2)

Publication Number Publication Date
WO2001027282A1 WO2001027282A1 (en) 2001-04-19
WO2001027282A8 true WO2001027282A8 (en) 2001-08-16

Family

ID=10862753

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/028430 WO2001027282A1 (en) 1999-10-14 2000-10-13 Plant virus particles with exogenous internal eitopes

Country Status (16)

Country Link
EP (1) EP1235910A1 (en)
JP (1) JP2003534771A (en)
KR (1) KR100880477B1 (en)
CN (2) CN101591647A (en)
AR (1) AR026066A1 (en)
AU (1) AU785020B2 (en)
BR (1) BR0014861A (en)
CA (1) CA2387626A1 (en)
CO (1) CO5280142A1 (en)
CZ (1) CZ20021303A3 (en)
GB (1) GB9924352D0 (en)
IL (1) IL149077A0 (en)
MX (1) MXPA02003789A (en)
PL (1) PL354933A1 (en)
WO (1) WO2001027282A1 (en)
ZA (1) ZA200202815B (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003000855A2 (en) * 2001-06-21 2003-01-03 Uab Research Foundation Chimeric capsid proteins and uses thereof
US8101189B2 (en) 2002-07-05 2012-01-24 Folia Biotech Inc. Vaccines and immunopotentiating compositions and methods for making and using them
AU2003281246A1 (en) 2002-07-05 2004-01-23 Denis Leclerc Adjuvant viral particle
WO2006041933A2 (en) 2004-10-05 2006-04-20 Diversa Corporation Improved vaccines
JP2009501001A (en) * 2005-06-01 2009-01-15 ダウ グローバル テクノロジーズ インコーポレイティド Production of multivalent virus-like particles
EP1909829A4 (en) * 2005-07-19 2009-11-11 Dow Global Technologies Inc Recombinant flu vaccines
EP2139993A2 (en) * 2007-04-27 2010-01-06 Dow Global Technologies Inc. Improved production and in vivo assembly of soluble recombinant icosahedral virus-like particles
WO2013003353A2 (en) * 2011-06-30 2013-01-03 Stc.Unm Plasmids and methods for peptide display and affinity-selection on virus-like particles of rna bacteriophages

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9108386D0 (en) * 1991-04-19 1991-06-05 Agricultural Genetics Co Modified plant viruses as vectors
GB9712282D0 (en) * 1997-06-12 1997-08-13 Innes John Centre Innov Ltd Epitope presentation system

Also Published As

Publication number Publication date
ZA200202815B (en) 2003-08-27
KR20020040868A (en) 2002-05-30
CZ20021303A3 (en) 2002-10-16
CN101591647A (en) 2009-12-02
GB9924352D0 (en) 1999-12-15
MXPA02003789A (en) 2002-09-30
AR026066A1 (en) 2002-12-26
KR100880477B1 (en) 2009-01-28
CN1471580A (en) 2004-01-28
BR0014861A (en) 2002-07-16
JP2003534771A (en) 2003-11-25
EP1235910A1 (en) 2002-09-04
CO5280142A1 (en) 2003-05-30
PL354933A1 (en) 2004-03-22
CA2387626A1 (en) 2001-04-19
AU785020B2 (en) 2006-08-24
IL149077A0 (en) 2002-11-10
AU1085201A (en) 2001-04-23
WO2001027282A1 (en) 2001-04-19

Similar Documents

Publication Publication Date Title
WO2001098333A3 (en) Modification of hepatitis b core antigen
WO2004042001A3 (en) Virus-like particles, methods of preparation, and immonogenic compositions
WO2004004761A3 (en) Adjuvant viral particle
EP1200109A4 (en) Inducing cellular immune responses to hepatitis c virus using peptide and nucleic acid compositions
WO2002000885A3 (en) Assembly of wild-type and chimeric influenza virus-like particles (vlps)
EP0953648A3 (en) Viral defective vaccine produced by transcomplementing cell line
WO2008115199A3 (en) Chimeric virus vaccines
PT1465987E (en) Production of viruses, viral isolates and vaccines
WO2003023032A3 (en) High throughput directed evolution by rational mutagenesis
WO1993000365A3 (en) Hepatitis c virus (hcv) polypeptides
CA2370372A1 (en) Porcine reproductive and respiratory syndrome vaccine, based on isolate ja-142
WO2004022729A8 (en) Method for the cultivation of primary cells and for the amplification of viruses under serum free conditions
WO2007008918A3 (en) Virus vaccines comprising envelope-bound immunomodulatory proteins and methods of use thereof
MY131143A (en) Proteins derived from white spot syndrome virus and uses thereof
EP2275131A3 (en) HCV Vaccines
WO2007046839A3 (en) New live virus vaccines
WO2001027282A8 (en) Plant virus particles with exogenous internal eitopes
WO2003023040A3 (en) Vaccinia virus mva-e3l-knockout-mutants and use thereof
WO2009014782A3 (en) Improved production and in vivo assembly of soluble recombinant icosahedral virus-like particles
EP1420819A4 (en) Sub-unit vaccine for infectious pancreatic necrosis virus
AU4195696A (en) Hepatitis e virus antigens and uses therefor
MXPA02012593A (en) Bvdv virus-like particles.
AU2002212555A1 (en) Yeast derived vaccine against ipnv
WO2004009763A3 (en) Use of vaccinia virus deleted for the e3l gene as a vaccine vector
WO2003037265A3 (en) Method of treating viral infections

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: C1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: C1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

CFP Corrected version of a pamphlet front page

Free format text: REVISED TITLE RECEIVED BY THE INTERNATIONAL BUREAU AFTER COMPLETION OF THE TECHNICAL PREPARATIONS FOR INTERNATIONAL PUBLICATION

WWE Wipo information: entry into national phase

Ref document number: 149077

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 10852/01

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2387626

Country of ref document: CA

Ref document number: PV2002-1303

Country of ref document: CZ

Ref document number: IN/PCT/2002/533/CHE

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 1020027004778

Country of ref document: KR

ENP Entry into the national phase

Ref document number: 2001 530485

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: PA/a/2002/003789

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2000972153

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020027004778

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 008167532

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2000972153

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: PV2002-1303

Country of ref document: CZ